Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Liabilities and Shareholders Equity: 2022-2025

Historic Liabilities and Shareholders Equity for InMed Pharmaceuticals (INM) over the last 4 years, with Jun 2025 value amounting to $15.6 million.

  • InMed Pharmaceuticals' Liabilities and Shareholders Equity rose 27.67% to $13.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.7 million, marking a year-over-year decrease of 8.21%. This contributed to the annual value of $15.6 million for FY2025, which is 31.78% up from last year.
  • Per InMed Pharmaceuticals' latest filing, its Liabilities and Shareholders Equity stood at $15.6 million for FY2025, which was up 31.78% from $11.8 million recorded in FY2024.
  • InMed Pharmaceuticals' 5-year Liabilities and Shareholders Equity high stood at $15.6 million for FY2025, and its period low was $11.8 million during FY2024.
  • Over the past 3 years, InMed Pharmaceuticals' median Liabilities and Shareholders Equity value was $14.1 million (recorded in 2023), while the average stood at $13.8 million.
  • As far as peak fluctuations go, InMed Pharmaceuticals' Liabilities and Shareholders Equity fell by 16.19% in 2024, and later skyrocketed by 31.78% in 2025.
  • InMed Pharmaceuticals' Liabilities and Shareholders Equity (Yearly) stood at $12.8 million in 2022, then increased by 10.31% to $14.1 million in 2023, then fell by 16.19% to $11.8 million in 2024, then surged by 31.78% to $15.6 million in 2025.